Place de la chimiothérapie de type témozolomide pour les astrocytomes intramédullaires de grade II de l'adulte : notre expérience

Temozolomide stabilized all 5 patients without any major toxicity. Based on this experience that needs to be confirmed, we consider that temozolomide should be envisaged within the therapeutic arsenal for progressive intramedullary grade II astrocytomas.